Drug agency Vivimed Labs
on Monday mentioned it has acquired approval from the Director General of Health Services
(DGHS) to fabricate and market Favipiravir tablets
in India, used for the treatment
of gentle to average instances of Covid-19. Vivimed Labs in receipt of Authorities of India (DGHS) approval to fabricate and market Favipiravir tablets within the strengths of 200 mg and 400 mg below Vivimed’s personal model identify ‘Favulous
‘ throughout India, the corporate mentioned in a regulatory submitting. It’s used for the remedy of gentle to average instances of Covid-19.
Favipiravir is without doubt one of the main oral anti-viral remedy accepted in varied international locations for the potential remedy of sufferers with gentle to average Covid-19 disease.
Ramesh Krishnamurthy, CEO of Vivimed Labs mentioned, “With big spike in Covid-19 instances being reported day by day in India, there may be an pressing want to offer extra remedy choices to healthcare professionals.
“We’re launching Favulous at a aggressive worth to make the drug accessible to increasingly more sufferers thereby making certain good well being and lowering their monetary burden. That is according to Vivimed’s dedication to be at forefront in India’s struggle towards Covid-19.”
The corporate mentioned it’ll work carefully with the varied governments and medical group to make sure availability of Favulous to sufferers throughout the nation.